Click (NASDAQ:CLIK) Stock Price Up 1.4% – Here’s What Happened

Click Holdings Limited (NASDAQ:CLIK)’s share price shot up 1.4% on Friday . The company traded as high as $1.52 and last traded at $1.44. 104,765 shares were traded during mid-day trading, a decline of 46% from the average daily volume of 192,340 shares. The stock had previously closed at $1.42.

Analyst Upgrades and Downgrades

Several analysts have issued reports on CLIK shares. Wall Street Zen upgraded shares of Click to a “hold” rating in a research report on Saturday, June 13th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Click in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Click Stock Up 1.4%

The stock has a 50-day simple moving average of $1.67 and a 200 day simple moving average of $2.98.

Click (NASDAQ:CLIK) last released its quarterly earnings data on Monday, May 11th. The company reported $0.10 earnings per share (EPS) for the quarter. The firm had revenue of $3.79 million for the quarter.

Institutional Investors Weigh In On Click

An institutional investor recently bought a new stake in Click stock. Renaissance Technologies LLC purchased a new stake in Click Holdings Limited (NASDAQ:CLIK) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 14,200 shares of the company’s stock, valued at approximately $25,000. Renaissance Technologies LLC owned 1.23% of Click at the end of the most recent reporting period.

Click Company Profile

Click Therapeutics, Inc (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.

Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review.